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Abstract 
Ischaemic stroke, accompanied by neuroinflammation, impairs blood-brain barrier integrity 
through a complex mechanism involving both protein kinase C (PKC) and urokinase. Using 
an in vitro model of human blood-brain barrier (BBB) composed of brain microvascular 
endothelial cells (HBMEC) and astrocytes, this study assessed the putative roles of these 
elements in BBB damage evoked by enhanced availability of pro-inflammatory cytokine, 
TNF-α. Treatment of HBMEC with TNF-α significantly increased the mRNA and protein 
expressions of all plasminogen-plasmin system (PPS) components, namely tissue 
plasminogen activator, urokinase, urokinase plasminogen activator receptor and plasminogen 
activator inhibitor-1 and also the activities of urokinase, total PKC and extracellular MMP-2. 
Inhibition of urokinase by amiloride abated the effects of TNF-α on BBB integrity and MMP-
2 activity without affecting that of total PKC. Conversely, pharmacological inhibition of 
conventional PKC isoforms dramatically suppressed TNF-α-induced overactivation of 
urokinase. Knockdown of PKC-α gene via specific siRNA in HBMEC suppressed the 
stimulatory effects of TNF-α on protein expression of all PPS components, MMP-2 activity, 
DNA fragmentation rates and pro-apoptotic caspase-3/7 activities. Establishment of co-
cultures with BMEC transfected with PKC-α siRNA attenuated the disruptive effects of TNF-
 on BBB integrity and function. This was partly due to elevations observed in expression of 
a tight junction protein, claudin-5 and partly to prevention of stress fibre formation. In 
conclusion, specific inhibition of PKC-α in cerebral conditions associated with exaggerated 
release of pro-inflammatory cytokines, notably TNF- may be of considerable therapeutic 
value and help maintain endothelial cell viability, appropriate cytoskeletal structure and 
basement membrane. 
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1. Introduction 
Blood-brain barrier (BBB) is located between cerebral circulation and the brain and accounts 
for the selective transition of ions and molecules between the two [1]. The BBB is composed 
of an endothelial cell lining surrounded by a continuous basement membrane and astrocyte 
endfeet as well as pericytes and neurons [2-4]. In addition to astrocyte endfeet, tight junctions 
also determine the overall tightness of BBB. They exist between adjacent endothelial cells 
and are formed by intricate relationships between claudin-5 and occludin proteins themselves 
and with the actin cytoskeleton. Taken together, these findings imply that any physical, 
chemical or humoral pathological stimulus that can alter the structure or function of any of 
the abovementioned components would undoubtedly alter the permeability of BBB [5, 6]. 
Neuroinflammation, characterised by an excessive generation of inflammatory cytokines, 
notably TNF-, has long been regarded a key phenomenon in breakdown of the BBB after an 
ischaemic stroke. Recent studies scrutinising the molecular causes of TNF-α-induced BBB 
damage have proven concurrent inductions of matrix metalloproteinase-2 (MMP-2), a 
basement membrane degrading enzyme and NADPH oxidase, the main enzymatic source of 
oxidative stress in cerebral vasculature, as key factors [7]. In these studies, diminished 
expression of tight junction proteins; reorganisation of actin cytoskeleton and the reduced 
viability of BBB-related major cell lines i.e. brain microvascular endothelial cells (BMEC) 
and astrocytes have also been shown to play pivotal roles in TNF-α-induced barrier damage 
[7, 8].  
Activation of plasminogen-plasmin system (PPS), especially tissue plasminogen activator 
(tPA) and urokinase plasminogen activator (uPA) after an ischaemic stroke may initiate the 
process of endogenous recanalisation. Plasminogen activators convert zymogen plasminogen 
into plasmin which then digests the fibrin in blood clot to restore blood flow to the occluded 
vessels and the downstream tissue. Increases in uPA mRNA and protein expressions have 
also been shown in various human cell lines such as microvascular and umbilical vein 
endothelial cells and breast epithelial cells exposed to TNF- [9-11]. Although elevations in 
intracellular calcium and NADPH oxidase activity can explain the enhanced activities of tPA 
and uPA during ischaemic injury, the nature of link between plasminogen activators and 
TNF- with reference to BBB integrity remains unexplored [12]. 
  
5 
 
Interestingly, activation of plasminogen is also implicated in the development of various 
inflammatory and immune responses which individually or collectively trigger extracellular 
proteolysis, loss of cell adhesion and disassembly of junctional complexes and consequently 
elicit apoptosis [10, 13]. As stimulation of apoptotic pathway by different proteins during 
both in vitro and in vivo ischaemic injury culminates in activation of caspase-3/7, inhibition 
of these enzymes with Z-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-
fluoromethylketone) has been shown to reduce cerebral infarct volume, tight junction 
disruption and BBB permeability [14-16].  
Protein kinase C (PKC) family of enzymes phosphorylate multiple targets on various proteins 
and are associated with tight junction and cytoskeletal reorganisation, endothelial barrier 
dysfunction, apoptosis, uPA overexpression, oxidative stress and MMP production [17-20]. 
Current evidence reveal that PKC- and PKC- isoforms play pivotal roles in TNF-α-
mediated endothelial barrier dysfunction in part through elevation of Rho-A activity [18, 21, 
22]. In support of these findings, inhibition of PKC-α in BMEC via its specific siRNA or 
inhibitor has been found to reduce the permeability of an in vitro model of human BBB 
exposed to hyperglycaemia or ischaemic injury [12, 23]. 
In light of the above, the current study investigates the link between PKC-α and PPS 
components with reference to functional alteration of in vitro cerebral barrier in the presence 
of TNF-α and attempts to scrutinise this link further in similar settings by looking at cell 
apoptosis, stress fibre formation and MMP activities.  
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2. Materials and Methods 
All chemicals used in this study were from Sigma (Dorset, UK) unless otherwise stated.  
2.1. Cell culture 
Human brain microvascular endothelial cells (HBMEC) and human astrocytes (HA) were 
purchased from TCS Cell Works Ltd (Buckingham, UK) and cultured up to and including 
passage 6 in a humidified atmosphere (75% N2, 20% O2, 5% CO2) at 37ºC in their respective 
specialised media (Sciencell Research Laboratories, San Diego, USA). Both media were 
supplemented with 1% penicillin/streptomycin mix and 1% endothelial growth supplement 
while 5% foetal bovine serum was added to the EC media, only 2% serum was added to the 
astrocyte media. To study the effects of TNF-α, in some experiments, cells grown to ~90% 
confluence were exposed to highly purified recombinant human TNF-α (5-10 ng/mL, R&D 
Systems, UK) for 6 h. In other experiments, the cells were co-treated for 6 h with TNF-α (10 
ng/mL) and an inhibitor for uPA (amiloride; 2.5 μM), PKC-α (Ro-32-0432; 0.05 μM) or 
PKC-β (LY333531; 0.05 μM).  
2.2. In vitro model of human BBB 
An in vitro model of human BBB composed of HBMEC and HA was established as 
previously described [23-26]. Briefly, HBMEC and HA were co-cultured to full confluence 
in their respective specialised media successively on the inner and outer sides of the 
Transwell inserts (polyester membrane, 0.4 µm pore size, Corning Costar, High Wycombe, 
UK). 
2.3. BBB experiments 
The integrity and function of the BBB were assessed as before by measurements of 
transendothelial electrical resistance (TEER) and paracellular flux of the permeability 
markers, sodium fluorescein (NaF, Mw: 376 Da) and Evan’s blue-labelled albumin (EBA, 
Mw: 67 kDa) across the in vitro model of human BBB [7]. 
2.4. Total PKC activity 
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Total PKC activity was measured in HBMEC lysates using the PepTag non-radioactive PKC 
activity assay kit (Promega, UK). Briefly, following the experimental treatments, the cells 
were harvested, homogenised by sonication in cold PKC extraction buffer. PKC was 
extracted by passing the supernatant over a 1 mL column of DEAE cellulose and eluting the 
PKC-containing fraction using PKC extraction buffer containing 200 mM NaCl. Samples 
were incubated for 30 min with a fluorescent substrate (PepTag C1 peptide), the reaction 
terminated by heat and separated into phosphorylated and nonphosphorylated substrates on a 
0.8% agarose gel. The portion of the gel containing the phosphorylated bands was excised 
and solubilised at 95ºC prior to addition of acetic acid to avoid solidification of the gel. The 
samples were placed in triplicates on a 96-well plate and absorbency was measured at 570 
nm. The results were expressed in units/mL according to the calculation guidelines of the 
manufacturer. 
 
2.5. Measurement of uPA activity 
The levels of total uPA activity were detected by an enzyme-linked immunosorbent assay. 
HBMEC were grown to confluence and exposed to the outlined treatment regimes. Following 
the treatments, the cell culture supernatants were collected and centrifuged at 1000 g for 10 
min at 4ºC to remove the excess cell debris from the culture media. Briefly, samples or 
standard for uPA (Calbiochem) were added in duplicate to 96-well Streptavidin-coated plates 
(Thermo Scientific, Loughborough, UK) that had been precoated with biotinylated PAI-1 
(300 ng/mL; Abcam, Cambridge, UK) and incubated for 2 h at room temperature. The plates 
were washed with PBS containing 0.05% Tween 20 before incubation with a primary 
antibody specific for uPA (rabbit; cat. no. sc-14019; 1:50; Santa Cruz Biotech, Heidelberg, 
Germany) for 2 h at room temperature. The plates were then washed and incubated with 
horseradish peroxidase-linked secondary antibodies (donkey anti-rabbit; Santa Cruz; cat. no. 
sc-2313; 1: 5000) and substrate solution for 20 min in the dark, respectively. The reactions 
were stopped by addition of stop solution (2 mM sulphuric acid) in each well and the optical 
densities were measured using a BMG LABTECH Omega plate reader set to 450 nm. The 
total uPA activity was calculated using the standard curves and normalised against the total 
protein concentrations as before [27]. 
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2.6. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
Confluent HBMEC were washed with ice-cold PBS, trypsinised and centrifuged at 4ºC for 10 
min at 2000 g. Total RNA extraction was performed using the GenElute mammalian total 
RNA kit according to the manufacturer’s instructions (Sigma-Aldrich). After determining the 
RNA concentrations in the samples by spectrophotometry, reverse-transcription was 
performed using the cloned AMV first-strand cDNA synthesis kit (Invitrogen, UK). For this, 
total RNA (2-10 µg) was mixed with 1 µl random primer and denatured at 70ºC for 3 min 
before placing on ice for 2 min. cDNA preparation was initiated by adding the RNA mixture 
to the master reaction mix containing 0.1 mM DTT, 10 mM dNTP, 5x cDNA synthesis 
buffer, 1.5 µL cloned AMV RT and 1 µL RNaseOUT™. The reaction mix was incubated at 
42ºC for 90 min. PCR was performed using a Mastercycle Gradient PCR device (Eppendorf 
Scientific). The sequences of the forward and reverse primers used to amplify uPA, uPAR, 
tPA and PAI-1 and 28S ribosomal RNA (internal control) are indicated in table 1. The 
condition for PCR reaction were as follows: initial denaturation at 94ºC for 45 sec followed 
by 35 cycles of denaturation at 94ºC (45 sec), annealing at 60-68ºC (1 min) and extension at 
72ºC (1 min) and a final extension for (10 min) at 72ºC. The annealing temperatures used 
were 62°C for uPA, tPA and PAI-1, 64°C for uPAR and 68°C for 28S. The PCR products 
were electrophoresed through 1% agarose gels containing 0.5 μg/mL ethidium bromide. The 
gels were then scanned on a G Box (Syngene) and the bands were quantified using the Gene 
snap software from Syngene.  
2.7. Immunoblotting 
Equal amount of total protein samples (50-65 μg) were electrophoresed on 10% SDS-PAGE 
gels before transferring onto polyvinylidene fluoride membrane (GE Healthcare, 
Buckinghamshire, UK). The membranes were then successively incubated with a 
combination of primary antibodies specific for β-actin (mouse; cat no: A5441; internal 
control; 1:30000; Sigma, Dorset, UK) and claudin-5 (rabbit; cat no: ab53765;  1:500; Abcam, 
Cambridge, UK), occludin (rabbit; cat. no. sc5562;  1:650), uPA (rabbit; cat no: sc-14019; 
1:400), uPAR (rabbit; cat no: sc-10815; 1:400), tPA (rabbit; cat. no. sc-15346; 1:250), PAI-1 
(rabbit; cat. no. sc-8979; 1:600) and infrared dye-conjugated appropriate secondary 
antibodies (goat anti-mouse; cat. no. 926-68020  and goat anti-rabbit; cat. no. 926-32211; 
1:30000; Li-Cor Biosciences, Cambridge, UK). All antibodies, other than those indicated 
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above, were from Santa Cruz Biotech (Heidelberg, Germany). The blots were visualised and 
analysed using the Li-Cor Odyssey infrared imaging system (Li-Cor Biosciences). 
2.8. Gelatin zymography 
The activities of MMP-2 and MMP-9 were measured by gelatin zymography. Equal amounts 
of culture media used to grow cells (5-10 μL) or total cellular protein (20-70 μg/mL) were 
electrophoresed on 10% SDS-PAGE gel containing 0.1% gelatin. The positive controls for 
MMP-2 and MMP-9 were also run on each gel. The gels were then washed for 30 min in 
2.5% Triton X-100 and incubated overnight at 37ºC in a buffer containing 50 mM Tris (pH 
7.5), 10 mM CaCl2, 50 mM NaCl and 0.05% Brij-35 (Calbiochem, UK). The gels were then 
stained for 2 h in 0.1% Comassie Brilliant Blue-G dye containing 25% methanol and 5% 
acetic acid and then destained for a minimum of 1 h in 50% methanol and 25% acetic acid. 
Bands were visualised and quantified using Li-Cor Odyssey infrared imaging system and the 
readings were normalised to “mg protein”.  
 2.9. F-actin staining 
The presence of stress fibres was assessed through F-actin staining in cells cultured to ~80% 
confluence on sterile glass coverslips and exposed to normal and experimental conditions. 
For this, the cell culture media were carefully aspirated and the cells were fixed and 
permeabilised in 4% paraformaldehyde/ PBS for 20 min and 0.1 % Triton X-100/ PBS for 15 
min, respectively. Cells were then blocked with 10% BSA/PBS for 30 min before staining 
actin microfilaments via rhodamine-labelled phalloidin dye (5 U/mL) for 30 min at room 
temperature away from light. The coverslips were washed and incubated in the dark with 
4',6-diamidino-2-phenylindole (DAPI) for 5 min at room temperature. The excess DAPI was 
removed and the coverslips were mounted using glycerol/PBS (3:1) and the edges were 
sealed by a nail polish. Slides were viewed by Zeiss Axio Observer fluorescence microscope. 
2.10. TUNEL staining 
TUNEL staining was performed using a DeadEnd colourimetric TUNEL system detection kit 
as per the manufacturer’s instructions (Promega, UK). Briefly, HBMEC cultured to ~90% 
confluence on glass coverslips were fixed and permeabilised as above before equilibrating for 
10 min in a solution containing potassium cacodylate (200 mM), Tris-HCl (25 mM), 
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dithiothreitol (0.2 mM), BSA (250 mg/L) and cobalt chloride (2.5 mM). To allow end-
labelling to occur, the coverslips were then incubated for 60 min with recombinant terminal 
deoxynucleotidyl transferase (rTdT) reaction mix containing equilibrium buffer (98 μL), 
biotinylated nucleotide mix (1 μL) and rTDT enzyme (1 μL). The reaction was then stopped 
by dipping coverslips into 20x SSC buffer before blocking and staining them with 0.3% H2O2 
and horseradish peroxidase-labelled streptavidin (500 mg/L; 1:500), respectively. TUNEL-
positive cells were then detected via diaminobenzidine which gave the dark brown staining to 
the apoptotic cells. Cells were viewed under Zeiss Axio Observer microscope and counted 
(TUNEL-positive vs total) from 3 different fields per coverslip before calculating mean 
values for these areas. 
2.11. Caspase-3/7 activity 
Caspase-3/7 activity assay was performed using Apo-ONE homogeneous caspase-3/7 kit 
(Promega, UK). Briefly, cells grown to ~95% confluence in 96-well plates were subjected to 
experimental conditions. Following the treatments, 100 L of media was removed from each 
well and replaced by 100 L of caspase-3/7 assay buffer containing the non-flourescent 
caspase substrate rhodamine 110,bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-L-aspartic acid 
amide; Z-DEVD-R110) to initiate the reaction. The 96-well plates were then frozen at -80°C 
overnight. On the following day plates were thawed on a plate shaker for 2 h before reading 
the fluorescence. The cleavage of the non-fluorescent caspase substrate by caspase-3/7 
produced the fluorescent rhodamine-110 which was read at excitiation wavelength 485 nm 
and emission wavelength 520 nm using BMG LABTECH Omega plate reader. Blanks were 
subtracted from the readings which then were normalised to “mg protein”.  
2.12. Small interfering RNA (siRNA) transfection 
Cells cultured to ~70% confluence were washed with sterile PBS to remove traces of serum 
and antibiotics. The transfection medium was prepared by diluting the DharmaFECT siRNA 
transfection reagent 4 (containing 5-50 nM ON-TARGET plus SMART pool siRNA 
oligonucleotides against human PKC-α) in serum-free media. HBMEC were incubated with 2 
mL of transfection media for 24 h. The next day the transfection medium was aspirated and 
fresh ECM was added. On day three, transfection was repeated after which the cells were 
exposed to relevant experimental conditions. Similar experiments were carried out with non-
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targeting siRNA pool. Ultimately, the cells were homogenised and the transfection efficiency 
was confirmed by Western analyses of PKC-α in the sample. The sequences of the 
oligonucleotides used in PKC-α SMARTpool were: UCACUGCUCUAUGGACUUA, 
GAAGGGUUCUCGUAUGUCA, UUAUAGGGAUCUGAAGUUA and UAAGGAACCA 
CAAGCAGUA. 
2.13. Cell viability assay 
To detect cytotoxic effects of different treatment regimens on cells, viability assays were 
carried out regularly. Briefly, an aliquot of cells was mixed with 0.1% Trypan blue for 5 min 
before counting 100 cells using a light microscope to calculate the percentage viability. 
2.14. Statistical analysis 
Data are presented as mean±SEM. Statistical analyses were conducted using IBM SPSS 
statistics 20.0 software package. Mean values were compared by Student’s two-tailed t-test 
and one-way analysis of variance followed by Dunnett’s post-hoc analysis. P<0.05 was 
considered to be significant in all the experiments.  
 
3. Results 
3.1. TNF-α upregulates the mRNA and protein expressions of all PPS components 
Exposure of HBMEC to two different concentrations of TNF-α (5-10 ng/mL) for 6 h 
significantly increased uPA, uPAR, PAI-1 and tPA mRNA and protein expressions compared 
to control cells (Fig. 1A-D).  
3.2. TNF-α perturbs BBB integrity and function  
TNF-α (10 ng/mL) significantly compromised the integrity and function of the selected in 
vitro model of human BBB as evidenced by marked decreases in TEER values and 
concomitant increases in flux of both low and high molecular weight paracellular 
permeability markers, namely NaF (376 Da) and EBA (67 kDa). However, while inhibition 
of uPA by amiloride (2.5 μM) attenuated the extent of TNF--induced barrier damage, 
application of amiloride on its own had no profound effect on barrier integrity or function 
(Fig. 2A-C).  
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3.3. Effects of TNF-α on MMP and total PKC activities 
Exposure of HBMEC to TNF-α (10 ng/mL) for 6 h led to dramatic increases in both total 
PKC and extracellular MMP-2 activities where no difference in intracellular MMP-2 activity 
was observed. Interestingly, while amiloride neutralised TNF-α-mediated increases in 
extracellular MMP-2 activity, it had no effect on that of the total PKC (Fig. 3A-C).  
3.3. TNF-α augments uPA activity through activation of protein kinase C-/ 
TNF-α caused a significant increase in endothelial cell uPA activity which was diminished by 
the inhibitor of PKC-β (0.05 μM) and normalised by that of PKC-α (0.05 μM). The use of 
either inhibitor alone did not significantly affect uPA activity (Fig. 4A). Although PKC-α 
inhibitor used in the current study displays a high specificity for this particular isoform, it has 
also been reported to suppress the activity of other PKC isoforms albeit with substantially 
lower IC50 values. To reveal whether, and to what extent, PKC-α contributes to TNF--
mediated disruption of the BBB and regulates the mechanisms associated with this 
phenomenon, PKC-α specific siRNA was employed to switch off its transcriptional activity. 
Subsequent immunoblotting tested the efficacy of transfection experiments in that non-target 
siRNAs were used as controls (Fig. 4B).  
3.4. Silencing PKC-α attenuates the effects of TNF- on PPS components and MMP 
activity 
Knockdown of PKC-α gene in HBMEC slightly but significantly reduced TNF--mediated 
elevations observed in uPA, tPA, uPAR and PAI-1 protein expressions, indicating that PKC-
α acts upstream to all PPS components. Similar to these, transfection with PKC-α siRNA also 
significantly reduced both extracellular and intracellular MMP-2 activities compared to cells 
transfected with non-target siRNA (Figure 5A-F).  
3.5. PKC- is involved in the deleterious effects of TNF-α on tight junction protein 
expressions, BMEC viability and cytoskeleton 
Treatments with TNF-α substantially diminished the level of claudin-5 and occludin protein 
expressions in BMEC. Suppression of PKC-α activity abolished these decreases and also 
produced selective increases in claudin-5 expression (Fig. 6A-B). Inhibition of PKC-α also 
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decreased the levels of TNF-α-induced DNA fragmentation and pro-apoptotic caspase-3/7 
activities in BMEC where formation of stress fibres also appeared to decrease (Fig. 7A-D).  
3.6. Effects of PKC-α silencing on BBB integrity and function 
As indicated above, TNF-α markedly impaired in vitro barrier integrity and function as 
proven by reduced TEER and increased flux of NaF and EBA, respectively. Establishment of 
co-cultures with BMEC transfected with PKC-α siRNA significantly attenuated the effects of 
TNF-α on BBB integrity and function (Figure 8A-C). 
 
4. Discussion 
Spontaneous cerebral artery recanalisation after an acute ischaemic attack is observed in 
almost a quarter of patients and is closely correlated with better survival rates and outcome 
largely due to the presence of still salvageable penumbral tissue during the early phases of 
stroke [28]. Although useful for post-ischaemic endogenous recanalisation, activation of PPS 
involving uPA, its specific receptor uPAR and tPA is also closely implicated in the initiation 
and progression of various neurovascular complications including degradation of basement 
membrane and BBB failure [10, 13]. Considering the excessive release of inflammatory 
cytokines during an ischaemic attack and in light of our recent studies exhibiting the barrier-
disruptive function of TNF-, this study examined the putative involvement(s) of PPS 
components and associated downstream mechanisms in TNF--mediated BBB damage [7, 
8]. In this context, our initial studies assessing the effects of two pathologically relevant 
concentrations of TNF- (5-10 ng/mL) have shown significant increases in mRNA and 
protein levels of all PPS components. Similar specific increases in uPA mRNA and protein 
levels have previously been reported in human foreskin microvascular endothelial cells 
exposed to TNF-in hypoxic conditions [11]. The transcriptional and translational increases 
in uPA appeared to be reflective of that seen in its activity. Given that a selective increase in 
tPA activity failed to alter BBB integrity and function under normoxic and ischaemic 
conditions, TNF-α does not modulate tPA activity and a significant proportion of tPA in brain 
microvessels appears to exist in an inactive complex with PAI-1, the current study focussed 
solely on uPA activity [27, 29, 30]. Furthermore, it is anticipated that TNF-α-mediated 
increases observed in endothelial cell PAI-1 mRNA and protein expressions would tilt the 
balance from free tPA to tPA/PAI-1 complex even further and may actually provide a 
  
14 
 
compensatory mechanism against its potentiating impact on plasminogen activator activity in 
inflammatory settings.  
Using an in vitro model of human BBB consisting of BMEC and HA, this study has shown 
that inhibition of uPA has dramatically attenuated, but not neutralised, the detrimental effects 
of TNF- on barrier integrity and function. Marked increases in TEER and concomitant 
decreases in paracelluar flux verified this notion and pinpointed the involvement of other 
mechanisms in this phenomenon. Previous studies scrutinising the barrier-protective effects 
of targeting uPA (by amiloride) or uPAR (by anti-uPAR antibody) activity have attributed the 
observed benefits to concurrent attenuations of endothelial MMP-2 and NADPH oxidase 
activities in ischaemic conditions [27, 31, 32].  
NADPH oxidases make up a family of superoxide anion-generating enzymes that are induced 
by coupling of its catalytic subunit, Nox with other subunits e.g. p22-phox and p47-phox and 
act as downstream mediators of various PKC isoforms. Out of the seven isoforms of Nox 
identified to date, only Nox2 appears to play a tangible role after stroke [33].  Indeed, a 
steady increase in Nox2 protein expression in penumbral endothelial cells and microglia has 
been observed until day three following middle cerebral artery occlusion and Nox2-deficient 
mice develop considerably smaller cerebral infarcts after a similar insult [34, 35]. Similarly, 
while increases have been reported in Nox4 and Nox1 protein expressions in human and 
rodent cerebral vessels after stroke, their roles remain rather obscure in that there are reports 
showing that knockdown of Nox1 or Nox4 gene in mice led to or failed to show 
neuroprotection [36].  
MMPs are a family of zinc-dependent endopeptidases that degrade extracellular matrix and 
basement membrane proteins while promoting BBB malfunction by severely disrupting brain 
endothelial cell anchoring and matrix-endothelial cell signalling [37-39]. The relevance of 
over or uncontrolled expression of MMPs to TNF-α-induced cerebral barrier and tissue 
damage has been reported in various in vitro and in vivo studies [40-42]. Overactivation of 
various MMP isoforms, in particular MMP-1, -2, -3 and -9 has subsequently been connected 
to TNF-α-induced BBB hyperpermeability [7, 43-45]. In support of this, the intracerebral 
injection of TNF-α into rat brain was shown to induce MMP-9 activation and BBB disruption 
where inhibition of MMP by a synthetic MMP inhibitor, Batimastat, markedly reduced the 
capillary permeability [45]. In accordance with these data, the current study also shows a 
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significant but selective increase in extracellular, but not in intracellular, MMP-2 activity in 
TNF-α-treated HBMEC. Although the inability of TNF- to augment basal intracellular 
MMP-2 activity may in part explain this, excretion of intracellular MMPs to extracellular 
space for activation to combat cellular stress like TNF- is also likely to play a role. As most 
MMPs respond to the early stage of stimuli at transcriptional levels and are synthesised as 
intracellular isoforms [46], our data suggest that treatments with TNF-α for 6 h adequately 
accelerate MMP-2 gene transcription and ensuing secretion from cytosol. 
As expected from its BBB-protective effects, amiloride effectively neutralised the effects of 
TNF- on extracellular MMP-2 protein expression. However, it displayed no impact on 
intracellular isoform which was in contrast to its equally suppressive effects on both MMP-2 
isoforms in experimental settings of ischaemic injury where inhibition of PKC-α was also 
proven to be equally effective [27]. Interestingly, in the present study the inhibition of PKC-α 
via specific siRNAs also abolished the TNF-α-mediated increases seen in extracellular MMP-
2 activity and diminished the level of intracellular isoform below the levels seen in TNF--
untreated control cells. Similar decreases in pro-MMP-2 and membrane type 1-MMP 
expressions were previously obtained with PKC-α inhibition in bovine pulmonary artery 
smooth muscle cells subjected to TNF-α [20]. Collectively, these data suggest PKC-α as a 
better therapeutic target in preventing TNF-α-evoked cerebral barrier damage.  
Considering that TNF-α-mediated increases in human dental pulp and umbilical vein 
endothelial cell uPA levels were regulated by PKC [19, 47], we investigated the specific 
correlation between HBMEC uPA activity and two different PKC isoforms known to have 
profound relevance to BBB integrity i.e. PKC-α and PKC- Although inhibition of both 
isoforms significantly mitigated uPA activity, the magnitude of decreases appeared to be 
grater with PKC-α inhibition. Hence, this particular isoform was targeted during the rest of 
the study using its specific siRNA. Taken together with the inability of amiloride to diminish 
TNF-α-induced total PKC activity, these results confirmed the upstream localisation of PKC 
to uPA similar to a study revealing attenuation of TNF-α-induced uPA overexpression in 
human umbilical vein endothelial cells by three different PKC inhibitors, namely H-7, 
staurosporine, and calphostin C [19].  
Like MMP-2 and uPA, specific targeting of PKC-α activity by its siRNA also effectively 
decreased the protein expression of other PPS components. As non-targeting siRNAs failed 
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to influence the TNF--triggered increases in MMP-2-activity and PPS protein expressions, 
it is safe to state that inhibition of PKC-α subdues the pathways downstream to uPA and 
vitiates their deleterious effects on the cerebral barrier. Indeed, significant attenuation of 
permeability across co-cultures established by HBMEC transfected with PKC- siRNA 
confirmed this assumption [18, 22]. Enhanced expression or normalisation of claudin-5 and 
occludin, tight junction proteins, by PKC- knockdown in part accounts for its barrier-
protective effects [48]. Considering that silencing of PKC-α led to elevation of both protein 
expressions in HBMEC regardless of their exposure to TNF-, it is plausible to speculate that 
the observed increases may largely stem from an increased translational activity rather than 
prevention of their degradation or redistribution. Understanding how tight junctions may 
become vulnerable to damage by TNF- may lead to efficacious prevention and treatment of 
ischaemic stroke-mediated development of brain oedema, the main cause of death within the 
first week after a stroke. The functional relevance between the level of tight junction proteins 
and the cerebral barrier integrity has previously been shown in a model of transient ischaemic 
stroke where reperfusion injury-evoked BBB openings were closely linked to the diminished 
expressions of occludin, claudin-5 and ZO-1 [49]. 
Increases in actin stress fibre formation with TNF-α have previously been associated with 
endothelial gap formation, tight junction protein disassembly and subsequent promotion of 
endothelial barrier dysfunction [22]. In this study, HBMEC grown under normal conditions 
displayed thick cortical F-actin staining and had spindle-shaped morphology. In contrast, 
cells exposed to TNF-α possessed elongated morphology and thick stress fibres traversing the 
cells like those reported in human umbilical vein endothelial cells incubated with TNF-α for 
8-24 hours [50]. Once formed, stress fibres produce a tensile centripetal force to pull 
junctional protein inward to disrupt junctional complex and form paracellular openings. 
Although several mechanisms, including activation of vascular endothelial growth factor and 
NF-B are implicated in ischaemic injury-mediated junctional breakdown, TNF-α-mediated 
overactivation of PKC-α has been coupled to cytoskeletal reorganisation in mouse BMEC 
[22, 51, 52]. In the present study, restoration of normal cellular morphology and attenuation 
of stress fibres formation in HBMEC by PKC-α siRNA in addition to protection of in vitro 
barrier function add further weight to the findings of the latter study mentioned above.  
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Enhanced apoptosis of endothelial cells triggered by TNF-α is also implicated in cerebral 
barrier dysfunction [32, 53]. Indeed, marked increases in TUNEL staining, a hallmark of 
DNA fragmentation and pro-apoptotic caspase-3/7 activities in HBMEC support this notion. 
Activation of caspase-3/7 by TNF-α has previously been linked with dissolution of tight 
junctions and shown to induce human brain endothelial cell apoptosis and paracellular 
permeability [54]. Significant weakening of DNA fragmentation and caspase-3/7 activities by 
PKC-α knockdown, but not non-targeting siRNAs, alongside the preservation of cerebral 
barrier integrity indicate the disruptive role of HBMEC apoptosis in inflammatory cytokine-
induced barrier failure. The data also further confirm the therapeutic value of targeting PKC-
α in clinical settings associated with exaggerated synthesis or release of pro-inflammatory 
cytokines like TNF-α while suggesting the concomitant involvement of other TNF--induced 
mediators in the process. Although not studied here, it is probable that PKC-α-induced 
translocation of an active form of pro-apoptotic Bax protein into the outer mitochondrial 
membrane and subsequent increases in cytochrome C and reactive oxygen species production 
along with mitochondrial network fragmentation may also contribute to HBMEC apoptosis  
[55, 56]. Previously reported requirements for increases in PKC-α protein expression or 
activity to enhance glioma and breast cancer cell survival necessitate the in depth 
investigation of downstream mechanisms involved. However, the overt differences in 
characteristics of these cell lines, namely endothelial versus cancerous cells cannot be 
dismissed in this context [57, 58]. 
There are some limitations to this study. Despite the existence of a well-documented cross-
talk between HBMEC and astrocytes in the current model, the absence of other components 
of the neurovascular unit i.e. neurons, pericytes and microglia that affect the integrity and 
function of the BBB and the CNS as a whole should be noted here [7, 8]. Hence, it is 
essential to confirm the results presented in this study in in vivo settings by using an animal 
model of transient ischaemic stroke accompanied by excessive release of pro-inflammatory 
cytokine TNF-. It is noteworthy here that other PKC isoforms, namely nPKC- and aPKC- 
that appear to regulate tight junctional assembly and BBB integrity during experimental 
hypoxia and posthypoxic oxygenation may also be involved in the barrier-disruptive effects 
of TNF- [59]. It is also noteworthy that TNF--mediated induction of pro-inflammatory 
cytokine IL-6 and its receptor GP130 in BMEC may also contribute to its barrier-disruptive 
effects due to downregulation of both tight and adherens junctions [60]. 
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In conclusion, the current study reveals that excessive bioavailability of TNF-α severely 
disrupts the integrity and function of an in vitro model of human BBB through successive 
activations of PKC-α and MMP-2 and associated induction of uPA alongside the other PPS 
components, tight junctional complex disintegration, endothelial cell structural malformation 
and apoptosis. Since inhibition of PKC-α activity can effectively negate the deleterious 
effects of TNF-α on HBMEC, targeting this particular signalling pathway may be of 
therapeutic value in ischaemic stroke and other cerebrovascular diseases accompanied by 
abundant release of pro-inflammatory cytokines, notably TNF-α.  
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Figure Legends 
Figure 1 – 2 columns 
TNF-α increased mRNA and protein expressions of all plasminogen-plasmin system 
coponents. HBMECs were exposed to TNF-α (5-10 ng/mL) for 6 h before measurement of 
uPA (A), uPAR (B), tPA (C) and PAI-1 (D) mRNA and protein expressions. The readings 
were normalised to the levels of 28S rRNA for mRNA and β-actin for protein expressions, 
respectively. TNF-α caused significant increases in mRNA and protein levels of all PPS 
components in HBMEC as compared with controls. Data are expressed as mean±SEM from 9 
different experiments. *p<0.05 vs control, †p<0.05 vs TNF-α (5 ng/mL). 
 
Figure 2 – 1 column 
Amiloride ameliorated the detrimental effects of TNF-α on BBB integrity and function. 
HBMEC-HA co-cultures were exposed to 6 h TNF-α (10 ng/mL) in the absence or presence 
of an inhibitor for uPA (amiloride, 2.5 μmol/L). TNF-α significantly impaired BBB integrity 
and function as shown by a reduction in TEER (A) and increases in NaF (B) and EBA (C) 
flux volumes, which were prevented by amiloride treatment. Data are expressed as 
mean±SEM from 12 different experiments. *p<0.05 vs control, †p<0.05 vs TNF-α (10 
ng/mL), #p<0.05 vs amiloride + TNF-α. 
 
Figure 3 – 1 column 
TNF-α enhanced MMP-2 and total PKC activities. TNF-α (10 ng/mL) significantly increased 
total PKC activity and extracellular pro-MMP-2 levels in endothelial cells without affecting 
that of intracellular MMP-2 (A-C). Inhibition uPA activity by amiloride normalised 
extracellular pro-MMP-2 levels but appeared to be ineffective in the case of total PKC 
activity. Data are expressed as mean±SEM from 12 different experiments. *p<0.05 vs control, 
†p<0.05 vs TNF-α (10 ng/mL), #p<0.05 vs amiloride + TNF-α. 
 
Figure 4 – 1 cloumn 
Inhibition of PKC-α and PKC-β attenuated the effects of TNF- on total uPA activity. 
HBMEC were exposed to 6 h TNF-α (10 ng/mL) in the absence or presence of an inhibitor 
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for PKC-α (Ro-32-04-32, 0.05 μM) or PKC-β (LY333531, (0.05 μM). Both inhibitors 
significantly reduced TNF-α-induced increases in endothelial cell total uPA activity (A). 
Knockdown of PKC-α by specific siRNA reduced PKC-α protein expression in HBMEC 
where non-target (NT) siRNA had no effect on the expression (B). Data are expressed as 
mean±SEM from 7 different experiments. *p<0.05 vs control, †p<0.05 vs TNF-α (10 ng/mL), 
#p<0.05 vs PKC-α + TNF-α.  
 
Figure 5 – 2 columns 
PKC-α gene knockdown attenuates the protein expression of all PPS components as well as 
MMP-2 activity. HBMECs transfected with non-target (NT) siRNA or PKC-α siRNA were 
cultured in the absence or presence of TNF-α (10 ng/mL) for 6 h. Silencing of PKC-α alone 
in HBMEC significantly attenuated the effects of TNF- on all PPS proteins as evidenced by 
Western analyses (A-D). Transfection with PKC-α siRNA also diminished the levels of 
intracellular and extracellular MMP-2 activities as shown by gelatin zymograghy (E, F).  
Data are expressed as mean±SEM from 10 different experiments. *p<0.05 vs NT control, 
†p<0.05 vs NT + TNF-α (10 ng/mL). 
 
Figure 6 – 1 column 
TNF- reduced the protein expressions of tight junction proteins. HBMEC transfected with 
non-target (NT) siRNA or PKC-α siRNA were cultured in the absence or presence of TNF-α 
(10 ng/mL) for 6 h. Treatments with TNF-α decreased both claudin-5 and occludin protein 
levels. Knockdown of PKC-α gene alone via specific siRNA negated the effects of TNF-α 
(A, B). Data are expressed as mean±SEM from 6 different experiments. *p<0.05 vs NT 
control, †p<0.05 vs NT + TNF-α (10 ng/mL). 
 
Figure 7 – 2 columns 
TNF- increased apoptosis, caspase-3/7 activities and cytoskeletal reorganisation. HBMEC 
transfected with non-target (NT) siRNA or PKC-α siRNA were cultured in the absence or 
presence of TNF-α (10 ng/mL) for 6 h. Silencing of PKC-α gene alone in endothelial cells 
attenuated the effects of TNF- on apoptosis (A, C), caspase-3/7 activities (B) and on actin 
cytoskeleton (D). Arrows in C and D indicate the TUNEL-positive cells and F-actin stress 
  
25 
 
fibres. Scale bars = 20μm. Data are expressed as mean±SEM from 6 different experiments. 
*p<0.05 vs NT control, †p<0.05 vs NT TNF-α (10 ng/mL), #p<0.05 vs siRNA control cells. 
 
Figure 8 – 1 column 
PKC-α knockdown attenuated the deleterious effects of TNF- on BBB integrity and 
function. HBMEC-HA co-cultures established using endothelial cells transfected with non-
target (NT) siRNA or PKC-α siRNA were exposed to TNF-α (10 ng/mL) for 6 h. Silencing of 
PKC-α gene alone significantly attenuated the effects of TNF- on TEER (A) and the flux of 
NaF (B) or EBA (C).  Data are expressed as mean±SEM from 6 different experiments. 
*p<0.05 vs NT control, †p<0.05 vs NT + TNF-α (10 ng/mL), #p<0.05 vs PKC- siRNA 
control. 
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TABLE 1. Forward and reverse primers used in RT-PCR 
 
PPS component Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
uPA TAGGCTCTGCACAGATGGAT GTGAGGATTGGATGAACTAGGC 
tPA GACGCTGTGAAGCAATCATGGA CTGGGTTTCTGCAGTAGTTGTG 
uPAR GATCCAGGAAGGTGAAGAAGG GCAGGAGACATCAATGTGGTT 
PAI-1 GTCACATTGCCATCACTCTTGT GGACTTCCTGAGATACGGTGAC 
28S RNA AAACTCTGGTGGAGGTCCGTAGCGGTCCTG GCCAGTTCTGCTTACCAAAAGTGGCCAACT 
 
Data are expressed as mean  SEM (n=9). *P< 0.05. 
 
 
